Healthcare Meta Ad Creative Archetype Mix: What India's Top Brands Actually Run in 2026
Why archetype mix matters more than creative volume
Most Indian healthcare founders we talk to obsess over a single number: how many ads is the competitor running. That number is misleading on its own. A 60-ad library running 90% video tells you something very different from a 60-ad library running 70% carousel. Mix is the leading indicator of strategy. Volume is the lagging indicator of budget.
The Meta ad library does not show spend. It shows survivorship. A creative that's still running on day 35 either works or someone forgot to turn it off — and at the spend levels India's top hospital chains and aesthetic networks operate at, nobody forgets to turn off a losing ad for a month. So sustained archetype mix becomes a usable proxy for "what's converting."
The 2026 vertical benchmark table
This table is drawn from Prism Spy data on the top 8–12 advertisers per vertical in the April–June 2026 window. "Survivor mix" means creatives still live in the library 21+ days after first appearance.
| Vertical | Static | Short video | Carousel | UGC / testimonial |
|---|---|---|---|---|
| IVF & fertility | 38% | 14% | 34% | 14% |
| Aesthetic / derma clinics | 32% | 28% | 12% | 28% |
| Hair transplant | 22% | 34% | 18% | 26% |
| Dental chains | 48% | 20% | 20% | 12% |
| Eye / LASIK | 52% | 18% | 22% | 8% |
| Multispecialty hospitals | 62% | 22% | 10% | 6% |
| Oncology centres of excellence | 68% | 16% | 10% | 6% |
| D2C health (probiotics, hair, weight) | 26% | 32% | 16% | 26% |
Reading the table without making it a religion
A few patterns are real and worth internalising:
- The higher the ticket size, the more static survives. Oncology and multispecialty (₹40k–₹4L procedures) lean static-and-doctor-card heavy. Trust is the conversion blocker, not curiosity.
- The higher the aesthetic stakes, the more UGC survives. Hair transplant and derm clinics burn through static — UGC and before-after video do the conviction lift.
- Carousel only wins where the buyer needs a checklist. IVF wins on carousel because the patient needs price + process + success rate in one swipe. Hospitals don't — they win on consultant credentials.
- Reels-style 9:16 video is normalised everywhere now. Even hospitals that resisted vertical video in 2024 are at 20%+ in 2026. The format is no longer optional.
Three failure patterns we see Indian clinics make
1. Copying D2C ratios into clinical verticals
An Indian dental chain we audited in May 2026 had pushed UGC to 38% of its live ads — modelled on a D2C nutraceutical brand the founder admired. CPQL had drifted from ₹420 to ₹780 over four months. Once they re-weighted static doctor-credential cards to 45%+, CPQL settled back under ₹500 inside six weeks. UGC is conversion fuel for impulse purchases. Dental implant is not impulse.
2. Going all-in on video because "video is the future"
A Bengaluru IVF centre ran 78% short-form video for two quarters in 2025. Their carousel-heavy competitor — same city, similar consultant strength — converted at roughly half the CPQL. Carousel won because the IVF buyer wants to read, not be entertained. The video budget was reallocated; CPQL fell ~31%.
3. Running zero UGC because "we don't do testimonials, NMC code"
The NMC advertising code restricts patient testimonials in medical specialties, but it does not prohibit anonymised patient stories, doctor-narrated case discussions, or staff-shot day-in-the-life content. A blanket "no UGC" stance leaves the entire archetype unused. Most aesthetic chains we track work around this with doctor-led UGC and anonymised pre/post — both are compliant when framed correctly.
How to use Prism Spy to build your own archetype baseline in 30 minutes
- Pick your 5 closest competitors — same city or same procedure mix. Not the national giants.
- Pull their last 90 days of ad library activity in Prism Spy. Filter to "still active" creatives only.
- Tag each surviving creative by archetype (static / video / carousel / UGC). Prism Spy does this auto-tag, but verify edge cases manually.
- Average across the 5. That is your local survivor mix.
- Diff your own library against the local mix. Anything off by >15 percentage points needs a thesis, not just a defence.
What to ignore in archetype analysis
Three things look like signal but aren't:
- One-off "viral" creatives. A single Reel doing well does not justify reweighting. Look at the surviving mix.
- Brand films. Most healthcare brand films in India run for under 14 days. They are PR exercises, not performance creative. Strip them out of the count.
- Job posting ads. Hospitals run heavy nurse/technician recruitment on Meta. Prism Spy filters these out by default — make sure your manual analysis does too.
What changes in the next two quarters
Three shifts we expect by Q4 2026 based on what's already in the library:
- UGC ratios in hospitals will double from 6% to 12%. Three of India's largest hospital chains have already started running doctor-led 9:16 narrative video in May-June. This will normalise.
- Carousel will eat into static for dental. Multi-clinic dental chains are starting to use carousel to differentiate by branch, doctor, and procedure. We expect dental static to drop from 48% to ~40%.
- "AI-tell" UGC will get penalised. Visibly AI-generated talking-head UGC is starting to underperform versus human UGC. Survivor analysis already shows AI-tell creatives churning out of libraries faster.
Want your vertical's archetype mix benchmarked this week?
We run a free 45-minute Prism Spy walkthrough on your 5 closest competitors. You walk away with the survivor mix table for your category.
Book a free audit → WhatsApp ICG